Form 4: Humacyte CMO Granted 311,100 Restricted Stock Units

Humacyte's Chief Medical Officer, Shamik J. Parikh, was granted 311,100 restricted stock units, vesting in two tranches in 2026 and 2027.

Summary

• Shamik J. Parikh, Chief Medical Officer of Humacyte, Inc. (HUMA), acquired 311,100 shares of common stock.
• The acquisition occurred on November 16, 2025, at a price of $0 per share.
• The transaction represents a grant of restricted stock units (RSUs), where each RSU is a contingent right to receive one share of common stock.
• Following this transaction, Shamik J. Parikh beneficially owns 318,600 shares of common stock.
• The first 50% of the granted RSUs will vest on May 15, 2026.
• The remaining 50% of the RSUs will vest on May 15, 2027.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a key executive is generally a neutral to slightly positive event, as it aligns management's interests with shareholders over the long term. It is a routine compensation matter.

Positives

• The grant of restricted stock units aligns the Chief Medical Officer's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The use of a Rule 10b5-1 plan indicates a pre-planned and transparent approach to executive compensation and insider transactions.

Future Outlook

The future outlook indicates a structured vesting schedule for the Chief Medical Officer's equity compensation, with shares becoming fully vested by May 2027, aligning executive incentives with long-term company performance.

Industry Context

This RSU grant is a standard form of executive compensation in the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance and long-term success.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Medical Officer's incentives with shareholder value creation, as the compensation's ultimate value depends on the company's stock performance.
• Employees: This grant reflects the company's compensation strategy for key executives, potentially influencing overall employee compensation structures and retention efforts.

Next Steps

• The first 50% of the RSUs are scheduled to vest on May 15, 2026.
• The remaining 50% of the RSUs are scheduled to vest on May 15, 2027.

Key Dates

Keywords

Humacyte, HUMA, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, Shamik J. Parikh, Corporate Governance